Intracoronary Imaging and Transcriptomic Characteristics Before and After Maximum Lipid-Lowering Therapy: YELLOW-III Study of Evolocumab and Maximum Statin Therapy in Chronic Coronary Disease - PubMed
5 hours ago
- #intracoronary imaging
- #evolocumab
- #coronary artery disease
- The YELLOW-III study evaluated the effects of adding evolocumab to maximum statin therapy in 110 stable coronary artery disease patients.
- After 26 weeks of evolocumab treatment, significant improvements in plaque morphology were observed, including increased fibrous cap thickness (FCT) and reduced lipid core burden index (LCBI).
- Intravascular ultrasound showed a significant reduction in percentage atheroma volume.
- Transcriptomic analysis identified 922 up-regulated and 571 down-regulated genes post-treatment, with pathways related to mitochondrial function and cell survival being up-regulated.
- Machine learning models accurately predicted patient response to therapy using baseline gene expression profiles.
- The study concluded that evolocumab treatment leads to beneficial changes in plaque morphology, associated with restored mitochondrial function and reduced inflammation.